Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06412562 D1 Receptor Occupancy Study
NCT03686501Phase 1Completed
- Sponsor
- Invicro
- Start
- Sep 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of razpipadon in schizophrenia and Parkinson's disease (PD), sponsored by Invicro. Primary endpoints: D1 Receptor Occupancy (RO) in striatum at Day 1 and Relationship of D1 RO in the striatum versus plasma exposure at Day 1. Started Sep 2018; status: completed.
02
Drugs
razpipadon
03
Conditions
schizophreniaParkinson's disease (PD)
Beyond the preview
Go deeper on NCT03686501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03686501.